Bioconjugate Chemistry
Page 12 of 14
1
2
3
4
5
6
7
8
9
(11) Riebeling, C., Forsea, A. M., Raisova, M., Orfanos, C. E. and Geilen, C. C. (2002) The
bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br. J.
Cancer 87, 366ꢀ371.
(12) Muller, S., Migianu, E., Lecouvey, M., Kraemer, M. and Oudar, O. (2005) Alendronate
inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer
Res. 25, 2655ꢀ2660.
(13) Mackie, P. S., Fisher, J. L., Zhou, H. and Choong, P. F. (2001) Bisphosphonates
regulate cell growth and gene expression in the UMR 106ꢀ01 clonal rat osteosarcoma cell
line. Br. J. Cancer 84, 951ꢀ958.
(14) Shipman, C. M., Rogers, M. J., Apperley, J. F., Russell, R. G. and Croucher, P. I. (1997)
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antiꢀtumour activity.
Br. J. Haematol. 98, 665ꢀ672.
(15) Ledoux, D., HammaꢀKourbali, Y., Di Benedetto, M., FoucaultꢀBertaud, A., Oudar, O.,
SainteꢀCatherine, O., Lecouvey, M. and Kraemer, M. (2006) A new dimethyl ester
bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft
in nude mice. Anti-cancer drugs 17, 479ꢀ485.
(16) Caraglia, M., Marra, M., Naviglio, S., Botti, G., Addeo, R. and Abbruzzese, A. (2010)
Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin. Pharmacother. 11,
141ꢀ154.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(17) Tanvetyanon, T. and Stiff, P. J. (2006) Management of the adverse effects associated
with intravenous bisphosphonates. Ann. Oncol. 17, 897ꢀ907.
(18) Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L.,
Crino, L., Dirix, L., Gnant, M., Gralow, J., Hadji, P., Hortobagyi, G. N., Jonat, W., Lipton, A.,
Monnier, A., Paterson, A. H., Rizzoli, R., Saad, F. and Thurlimann, B. (2008) Guidance on the
use of bisphosphonates in solid tumours: recommendations of an international expert panel.
Ann. Oncol. 19, 420ꢀ432.
(19) Drake, M. T., Clarke, B. L. and Khosla, S. (2008) Bisphosphonates: mechanism of
action and role in clinical practice. Mayo Clin. Proc. 83, 1032ꢀ1045.
(20) Chebbi, I., MigianuꢀGriffoni, E., SainteꢀCatherine, O., Lecouvey, M. and Seksek, O.
(2010) In vitro assessment of liposomal neridronate on MDAꢀMBꢀ231 human breast cancer
cells. Int. J. Pharm. 383, 116ꢀ122.
(21) Seow, W. Y., Xue, J. M. and Yang, Y. Y. (2007) Targeted and intracellular delivery of
paclitaxel using multiꢀfunctional polymeric micelles. Biomaterials 28, 1730ꢀ1740.
(22) Benyettou, F., Lalatonne, Y., SainteꢀCatherine, O., Monteil, M. and Motte, L. (2009)
Superparamagnetic nanovector with antiꢀcancer properties: γꢀFe2O3@Zoledronate. Int. J.
Pharm. 379, 324ꢀ327.
(23) Greish, K., Fang, J., Inutsuka, T., Nagamitsu, A. and Maeda, H. (2003)
Macromolecular therapeutics: advantages and prospects with special emphasis on solid
tumour targeting. Clin. Pharmacokinet. 42, 1089ꢀ1105.
(24) Khalikova, E., Susi, P. and Korpela, T. (2005) Microbial dextranꢀhydrolyzing enzymes:
fundamentals and applications. Microbiol. Mol. Biol. Rev. 69, 306ꢀ325.
(25) Dang, W., Colvin, O. M., Brem, H. and Saltzman, W. M. (1994) Covalent coupling of
methotrexate to dextran enhances the penetration of cytotoxicity into a tissueꢀlike matrix.
Cancer Res. 54, 1729ꢀ1735.
(26) LeviꢀSchaffer, F., Bernstein, A., Meshorer, A. and Arnon, R. (1982) Reduced toxicity of
daunorubicin by conjugation to dextran. Cancer Treat. Rep. 66, 107ꢀ114.
(27) Onishi, H. and Nagai, T. (1986) Preparation of dextran T70ꢀmethotrexate conjugate and
dextran T70ꢀmycophenolic acid conjugate, and in vitro effect of dextran T70ꢀmethotrexate on
dihydrofolate reductase. Chem. Pharm. Bull. (Tokyo) 34, 2561ꢀ2567.
ACS Paragon Plus Environment